
Wednesday brought bad news for pharmaceutical firms Merck, Pfizer and Sanofi.
During its monthly meeting, members of the Danish Medicines Council debated an application from Merck and Pfizer, which had sought backing to use the former firm’s blockbuster drug Bavencio (avelumab) in combination with the latter’s Inlyta (axitinib) to treat kidney cancer.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app